In their most current integrative genomics studies the authors discovered the genetic and molecular features associated with MHC class I and II loss. They uncovered that MHC class II loss is most relevant in germinal center B (GCB) cell-type DLBCL as loss is associated with poor treatment outcome, a specific set of gene mutations characteristic of GCB-DLBCL, and an expression program that is associated with an immunologically “cold” microenvironment with a reduced T cell infiltrate.
Read More
On February 11, 2019, the International Day of Women and Girls in Science, the L’Oréal Foundation and UNESCO announced the 21st International Award For Women in Science, which honours outstanding women scientists from all over the world. These exceptional women are recognised for the excellence of their research in the fields of material science, mathematics and computer science. Their achievements will…
Read More
At a downtown Toronto hospital researchers are testing a remarkable hypothesis — that transplanting poop from a healthy person could treat bipolar depression. Dr. Valerie Taylor has people from around the world volunteering to be part of her pioneering clinical trial. “The goal is to see if we are improving symptoms and then to study their microbiome to see if we can…
Read More
The CIHR Institute of Human Development, Child and Youth Health (IHDCYH) in partnership with the Institute of Circulatory and Respiratory Health (ICRH); Institute of Health Services and Policy Research (IHSPR); Institute of Infection and Immunity (III); Institute of Indigenous Peoples’ Health (IIPH); Institute of Musculoskeletal Health and Arthritis (IMHA); and Institute of Neurosciences, Mental Health and Addiction (INMHA) is pleased…
Read More
CDRD, Canada’s national life sciences venture, is pleased to announce an increased commitment to Sitka Biopharma with a $1.2M investment. This new investment will enable Sitka and its partner Cancer Research UK (CRUK) to accelerate critical development activities and rapidly enter clinical trials of STK-01, Sitka’s lead product for the treatment of bladder cancer. Preclinical studies have established that Sitka’s candidate formulation significantly improved…
Read More

Cannabis for Health and Recreation: How Is Science Involved?

On October 17, 2018, the Cannabis Act came into effect, making recreational cannabis legally accessible across Canada. Despite this, there are still challenges in ensuring access to a consistent product across Canada, including in British Columbia, and questions remain about the physiological effects of long-term cannabis use. ​One of the major concerns is over the quality of cannabis reaching the public. Cannabis…
Read More
AbCellera, a technology leader in therapeutic antibody discovery from natural immune repertoires, today announced a multi-target and multi-year collaboration with Novartis. Under the agreement, AbCellera will apply its expertise in antibody discovery and its single-cell screening technology to advance programs on up to ten targets elected by the pharmaceutical partner. “AbCellera continues to build its reputation as a high-powered innovation…
Read More
Standard isolation of ctDNA involves the separation of plasma by centrifugation followed by column or magnetic bead-based purification of nucleic acids. While magnetic beads are more amenable to automation on liquid handlers, the upstream centrifugation remains largely manual and limits scalability. We present here a magnetic bead-based ctDNA isolation method that eliminates centrifugation steps to allow ctDNA purification directly from whole blood in 96-well plate format. Furthermore, this automated method minimizes manual handling of patient blood, lowering the risk of sample swaps and exposure to staff of blood borne infections.
Read More
As diseases of the central nervous system, such as Alzheimer’s disease, continue to impact the lives of Canadians, the National Research Council of Canada (NRC) and Aspect Biosystems are working to develop new therapeutic models that could lead to improved treatments in the future and better outcomes for patients suffering from brain disease. As one might expect, the brain is…
Read More
Mark Taylor has a front-row seat to the development and launch of some of Canada’s greatest health-tech innovations as the leader of the licensing and commercialization team at Toronto’s University Health Network (UHN), one of the largest health-care and medical research organizations in North America. Gene therapy to treat rare diseases in a single dose, devices that recognize brain tumours…
Read More